✦ LIBER ✦

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

✍ Scribed by Yasushi Takamatsu; Kazutaka Sunami; Hiroyuki Hata; Koji Nagafuji; Ilseung Choi; Masakazu Higuchi; Kimiharu Uozumi; Yasufumi Masaki; Kazuo Tamura; The Kyushu Hematology Organization for Treatment Study Group (K-HOT)

Publisher: Carden Jennings Publishing
Year: 2010
Tongue: English
Weight: 167 KB
Volume: 92
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-010-0673-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bortezomib, doxorubicin, and dexamethaso

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

✍ Sung Sook Lee; Cheolwon Suh; Bong-Seog Kim; Jooseop Chung; Young-Don Joo; Hun-Mo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 151 KB

A phase I safety study of enzastaurin pl

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

✍ Irene M. Ghobrial; Nikhil C. Munshi; Brianna N. Harris; Peipei Shi; Nichole M. P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB

Safety and efficacy of bortezomib and me

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

✍ James R. Berenson; Hank H. Yang; Robert A. Vescio; Youram Nassir; Russell Mapes; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 164 KB

Pixantrone dimaleate in combination with

Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma : Phase 1 study with a dose-expansion cohort

✍ Tomasz P. Srokowski; James E. Liebmann; Manuel R. Modiano; Gary I. Cohen; Barbar 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

## Abstract ## BACKGROUND: Pixantrone dimaleate (pixantrone) has been shown to have antitumor activity in leukemia and lymphoma in vitro models and to lack delayed cardiotoxicity associated with mitoxantrone in animal models. FND‐R, a combination regimen of fludarabine, mitoxantrone, dexamethasone

Phase III study of PSC-833 (valspodar) i

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) : A trial of the Eastern Cooperative Oncology Group

✍ William R. Friedenberg; Montserrat Rue; Emily A. Blood; William S. Dalton; Chaim 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 1 views